January, 18 2012
Kadimastem appointed Mr. Ofer Haviv as a director.
On January 18th , 2012 the Board of Directors of Kadimastem appointed Mr. Ofer Haviv as one of its directors. Mr. Haviv is the CEO of Evogene. Prior to being named CEO of Evogene in late 2004, Mr. Haviv held the positions of company COO and CFO from 2002 to 2004 and was involved in Evogene's spin-off from Compugen. Prior to the spin-off, he held the position of Director of Finance and Treasurer of Compugen for four years, during which time the company completed two private placements and an IPO on NASDAQ. Earlier, Mr. Haviv was the CFO of Klei Zemmer. He was also an auditor with a leading accounting firm belonging to a network of the "Big Five".
June, 13 2011
The new Chief Scientist, Mr. Avi Hasson visits Kadimastem.
On June 13th , 2011 the Chief Scientist of the Ministry of Industry, Trade and Labor, Mr. Avi Hasson visited the facilities and laboratories of Kadimastem Ltd. The Chief Scientist was accompanied by the Head of the Life Sciences branch, Dr. Ora Dar, and the biotech expert, Dr. Talia Ben-Neria. The delegation was presented with recent advances in R&D and with an expanded R&D program, including a tour at the new 700 square meters laboratory space that house the Drug Discovery and cellular therapy programs of Kadimastem. The company's acting CEO, Mr. Yossi Ben-Yossef, thanked the chief scientist and his staff for their support in the Israeli biotech in general and in stem cell/cell therapy companies like Kadimastem in particular. The chief scientist and his staff expressed their strong belief in the potential of Israeli cell therapy companies like Kadimastem.
In the picture Mr. Avi Hasson, the chief Scientist in the Israeli Ministry of Industry, Trade and Labor with Kadimastem's acting CEO, Mr. Yossi Ben-Yossef.
July 7, 2010
The Chief Scientist visits Kadimastem.
Kadimastem is proud to report a visit by the Chief Scientist of the Ministry of Industry, Trade and Labor, Dr. Eli Opper. The Chief Scientist was accompanied by the Head of the Life Sciences branch, Dr. Ora Dar, and the professional referee, Dr. Talia Ben-Neria. The delegation was presented with recent advances in R&D and with an expanded R&D program, including a tour at a new 700 square meters laboratory space that will house the Drug Discovery program.